380 filings
Page 9 of 19
8-K
yww61a
2 Apr 20
PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives
9:30am
8-K
v2y04
31 Mar 20
PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing
9:30am
NT 10-K
ey7n72
30 Mar 20
Notice of late annual filing
4:15pm
8-K
wyn5xs8t lv542npx7iq
9 Mar 20
PAVmed Announces FDA 510(k) Re-submission for its
9:30am
8-K
nma5zbeac e5ldafd6
2 Mar 20
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
9:30am
CORRESP
5e37 rdxr4l39
2 Mar 20
Correspondence with SEC
12:00am
8-K
us3qvg t6db
20 Feb 20
Regulation FD Disclosure
9:30am
8-K
180pz
18 Feb 20
PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline
9:30am
UPLOAD
4u1s 1153
18 Feb 20
Letter from SEC
12:00am
8-K
cqxocx dj0xf
11 Feb 20
Regulation FD Disclosure
9:30am
CORRESP
fg2votf 8zh5k0b4
30 Jan 20
Correspondence with SEC
12:00am
UPLOAD
nc7l6 qb5uvr3hlti
22 Jan 20
Letter from SEC
12:00am
8-K
ms463au3gy
13 Jan 20
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
9:30am
CORRESP
ispp8tt
8 Jan 20
Correspondence with SEC
12:00am
UPLOAD
r7o1d7gxwcihch rf0w
19 Dec 19
Letter from SEC
12:00am
NT 10-Q
yhso52odl
15 Nov 19
Notice of late quarterly filing
9:25am
D
j6xmu2r
7 Nov 19
$14M in debt / options / securities to be acquired, sold $14M, 2 investors
12:00am